CR20120134A - Derivados de pirazol que modulan la estearoil-coa-desaturasa - Google Patents
Derivados de pirazol que modulan la estearoil-coa-desaturasaInfo
- Publication number
- CR20120134A CR20120134A CR20120134A CR20120134A CR20120134A CR 20120134 A CR20120134 A CR 20120134A CR 20120134 A CR20120134 A CR 20120134A CR 20120134 A CR20120134 A CR 20120134A CR 20120134 A CR20120134 A CR 20120134A
- Authority
- CR
- Costa Rica
- Prior art keywords
- coa
- modulate
- desaturasa
- estearoil
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24763409P | 2009-10-01 | 2009-10-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20120134A true CR20120134A (es) | 2012-05-17 |
Family
ID=43066810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20120134A CR20120134A (es) | 2009-10-01 | 2012-03-20 | Derivados de pirazol que modulan la estearoil-coa-desaturasa |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20130011361A1 (https=) |
| EP (1) | EP2483264A1 (https=) |
| JP (1) | JP2013506638A (https=) |
| KR (1) | KR20120080226A (https=) |
| CN (1) | CN102574841A (https=) |
| AU (1) | AU2010302577A1 (https=) |
| BR (1) | BR112012007509A2 (https=) |
| CA (1) | CA2776294A1 (https=) |
| CL (1) | CL2012000797A1 (https=) |
| CO (1) | CO6761294A2 (https=) |
| CR (1) | CR20120134A (https=) |
| EA (1) | EA201200545A1 (https=) |
| EC (1) | ECSP12011837A (https=) |
| IL (1) | IL218294A0 (https=) |
| IN (1) | IN2012DN01913A (https=) |
| MA (1) | MA33693B1 (https=) |
| MX (1) | MX2012003938A (https=) |
| PE (1) | PE20121439A1 (https=) |
| PH (1) | PH12012500648A1 (https=) |
| SG (1) | SG178869A1 (https=) |
| TN (1) | TN2012000085A1 (https=) |
| WO (1) | WO2011039358A1 (https=) |
| ZA (1) | ZA201201390B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013056148A2 (en) | 2011-10-15 | 2013-04-18 | Genentech, Inc. | Methods of using scd1 antagonists |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| EA201991650A1 (ru) | 2017-01-06 | 2020-01-20 | Юманити Терапьютикс, Инк. | Способы лечения неврологических расстройств |
| CA3083000A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| BR112020019191A2 (pt) * | 2018-03-23 | 2021-01-05 | Yumanity Therapeutics, Inc. | Compostos e seus usos |
| MX2021008903A (es) | 2019-01-24 | 2021-11-04 | Yumanity Therapeutics Inc | Compuestos y usos de los mismos. |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| GB202012969D0 (en) * | 2020-08-19 | 2020-09-30 | Univ Of Oxford | Inhibitor compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1171465E (pt) | 1999-03-29 | 2004-12-31 | Uutech Ltd | Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes |
| RU2269354C2 (ru) | 1999-09-28 | 2006-02-10 | Байер Корпорейшн | Агонисты рецептора-3(r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения |
| EP1315831B8 (en) | 2000-02-24 | 2010-09-01 | Xenon Pharmaceuticals Inc. | Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents |
| US7232662B2 (en) | 2000-09-26 | 2007-06-19 | Xenon Pharmaceuticals Inc. | Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5 |
| EP2289510A1 (en) * | 2004-09-20 | 2011-03-02 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| EP1807085B1 (en) * | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
| CN101535303B (zh) * | 2006-08-15 | 2012-07-18 | 诺瓦提斯公司 | 适合用于治疗与升高的脂质水平有关的疾病的杂环化合物 |
| JP2010501567A (ja) * | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−ＣｏＡ不飽和化酵素（ＳＣＤ）阻害剤としての２−（ピラジン−２−イル）−チアゾールおよび２−（１Ｈ−ピラゾール−３−イル）チアゾール誘導体ならびに関連化合物 |
| KR20090053923A (ko) * | 2006-09-22 | 2009-05-28 | 노파르티스 아게 | 헤테로시클릭 유기 화합물 |
| US8068738B2 (en) * | 2007-02-21 | 2011-11-29 | Tte Technology, Inc. | System and method for decoding infra-red (IR) signals |
| WO2009103739A1 (en) * | 2008-02-20 | 2009-08-27 | Novartis Ag | Heterocyclic inhibitors of stearoyl-coa desaturase |
-
2010
- 2010-10-01 BR BR112012007509A patent/BR112012007509A2/pt not_active IP Right Cessation
- 2010-10-01 MX MX2012003938A patent/MX2012003938A/es not_active Application Discontinuation
- 2010-10-01 EA EA201200545A patent/EA201200545A1/ru unknown
- 2010-10-01 CN CN201080044452XA patent/CN102574841A/zh active Pending
- 2010-10-01 PH PH1/2012/500648A patent/PH12012500648A1/en unknown
- 2010-10-01 AU AU2010302577A patent/AU2010302577A1/en not_active Abandoned
- 2010-10-01 WO PCT/EP2010/064672 patent/WO2011039358A1/en not_active Ceased
- 2010-10-01 SG SG2012013066A patent/SG178869A1/en unknown
- 2010-10-01 JP JP2012531447A patent/JP2013506638A/ja active Pending
- 2010-10-01 KR KR1020127011127A patent/KR20120080226A/ko not_active Ceased
- 2010-10-01 US US13/391,900 patent/US20130011361A1/en not_active Abandoned
- 2010-10-01 EP EP10761003A patent/EP2483264A1/en not_active Withdrawn
- 2010-10-01 PE PE2012000427A patent/PE20121439A1/es not_active Application Discontinuation
- 2010-10-01 CA CA2776294A patent/CA2776294A1/en not_active Abandoned
- 2010-10-01 IN IN1913DEN2012 patent/IN2012DN01913A/en unknown
-
2012
- 2012-02-21 TN TNP2012000085A patent/TN2012000085A1/en unknown
- 2012-02-23 IL IL218294A patent/IL218294A0/en unknown
- 2012-02-24 ZA ZA2012/01390A patent/ZA201201390B/en unknown
- 2012-03-20 CR CR20120134A patent/CR20120134A/es unknown
- 2012-03-30 CL CL2012000797A patent/CL2012000797A1/es unknown
- 2012-04-03 CO CO12056222A patent/CO6761294A2/es not_active Application Discontinuation
- 2012-04-26 MA MA34807A patent/MA33693B1/fr unknown
- 2012-04-27 EC ECSP12011837 patent/ECSP12011837A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN01913A (https=) | 2015-07-24 |
| TN2012000085A1 (en) | 2013-09-19 |
| CN102574841A (zh) | 2012-07-11 |
| EA201200545A1 (ru) | 2012-12-28 |
| BR112012007509A2 (pt) | 2016-11-22 |
| CO6761294A2 (es) | 2013-09-30 |
| ZA201201390B (en) | 2012-10-31 |
| WO2011039358A1 (en) | 2011-04-07 |
| CL2012000797A1 (es) | 2013-08-09 |
| EP2483264A1 (en) | 2012-08-08 |
| JP2013506638A (ja) | 2013-02-28 |
| US20130011361A1 (en) | 2013-01-10 |
| PH12012500648A1 (en) | 2012-11-12 |
| IL218294A0 (en) | 2012-04-30 |
| PE20121439A1 (es) | 2012-11-06 |
| ECSP12011837A (es) | 2012-06-29 |
| AU2010302577A1 (en) | 2012-03-15 |
| MX2012003938A (es) | 2012-08-03 |
| CA2776294A1 (en) | 2011-04-07 |
| MA33693B1 (fr) | 2012-10-01 |
| KR20120080226A (ko) | 2012-07-16 |
| SG178869A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201000376A (es) | Compuestos organicos | |
| SV2010003650A (es) | INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| GT200900027A (es) | Compuestos organicos | |
| CR20110028A (es) | Derivados de pirimidina como inhibidores de cinasa | |
| GT201000023A (es) | Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met. | |
| MX351028B (es) | Determinadadas entidades, composiciones y metodos quimicos. | |
| CR20140106A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| CR20120134A (es) | Derivados de pirazol que modulan la estearoil-coa-desaturasa | |
| PY1411052A (es) | Compuestos heterocíclicos y usos de los mismos | |
| ECSP12011720A (es) | Compuestos heterocíclicos y usos de los mismos | |
| MX2015012456A (es) | Compuestos heterociclicos y usos de los mismos. | |
| ECSP11011340A (es) | Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen | |
| MX2015013042A (es) | Compuestos organicos. | |
| UY33314A (es) | Derivados de acido 1-amino-2-ciclopropiletilboronico | |
| CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
| CU20110207A7 (es) | Aril piridinas como inhibidoras de sintasa de aldosterona | |
| MX2019010602A (es) | Inhibidores de cdk. | |
| ECSP11011347A (es) | Nicotinamida sustituida como moduladores KCNQ2/3 | |
| UY32937A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119 | |
| MX384392B (es) | Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales. | |
| HN2010001537A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
| CL2012001759A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica. | |
| CR20120109A (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen |